Please select the option that best describes you:
How would you treat newly diagnosed metastatic HER2 positive breast cancer with liquid NGS revealed ERBB2 L755S mutation (a marker for resistance against trastuzumab)?
Answer from: Medical Oncologist at Community Practice
Neratinib
Sign in or Register to read more